Optimize drug therapy and monitor patient adherence. This test detects paliperidone (9-hydroxyrisperidone) only. For risperidone (parent) AND paliperidone (9-hydroxyrisperidone, metabolite), order Risperidone and Metabolite, Serum or Plasma (2007951).
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Pre-dose (trough) draw - At steady state concentration.
Lavender (EDTA), Pink (K2EDTA), or Plain Red.
Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).
Ambient: 2 weeks; Refrigerated: 2 weeks; Frozen: 2 months
|Therapeutic range:||Not well established|
|Proposed Dose-Related Range:||Paliperidone (9-hydroxyrisperidone): 20 - 60 ng/mL|
|Toxic range:||Not well established|
The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. Adverse effects to paliperidone therapy may include headache, nausea, dizziness, tachycardia, orthostatic hypotension and dyskinesia.
Laboratory Developed Test (LDT)
80342 (Alt code: G0480)
|Component Test Code*||Component Chart Name||LOINC|
- invega blood level